Elisabeth Schwartz | IR |
John Thero | CEO |
Mike Kalb | CFO |
Aaron Berg | CCO |
Craig Granowitz | CMO |
Joe Kennedy | General Counsel |
Louise Chen | Cantor |
Joel Beatty | Citi |
Michael Yee | Jefferies |
Welcome to Amarin Corporation's conference call to discuss its financial and operating results for the fourth quarter and full year 2018. This conference call is being recorded today, February 27, 2019. I would like to turn the conference over to Elisabeth Schwartz, Senior Director, Investor Relations of Amarin.
Please be aware that this conference call will contain forward-looking statements that are intended to be covered under the Safe Harbor provided by the Private Securities Litigation Reform Act. Examples of such statements include, but are not limited to, our current expectations regarding our commercial and financial performance, including levels of Vascepa prescriptions, Vascepa product and licensing revenues, costs and other commercial metrics, gross margin, expenditures and the adequacy of our financial resources.